Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in ALK-positive Non-small Cell Lung Cancer
View Full LandscapeTarget Indication
ALK-positive Non-small Cell Lung Cancer
Clinical Trial
NCT02336451Last updated: 2/9/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Zykadia
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
View on EMA